Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
André J Scheen. (2014) Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 839-857.
Read now
Read now
Articles from other publishers (21)
子乔 杨. (2023) Research Progress of Metformin in the Treatment of Cirrhosis with Diabetes. Advances in Clinical Medicine 13:02, pages 2254-2259.
Crossref
Crossref
Felix Gundling. (2022) Der hepatogene Diabetes – aktueller Stand der Diagnostik und TherapieHepatogenic diabetes—current status of diagnostics and treatment. Journal für Klinische Endokrinologie und Stoffwechsel 15:2, pages 42-52.
Crossref
Crossref
Pankaj Puri & Narendra Kotwal. (2022) An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. Journal of Clinical and Experimental Hepatology 12:2, pages 560-574.
Crossref
Crossref
Diego García-Compeán, Emanuela Orsi, Ramesh Kumar, Felix Gundling, Tsutomu Nishida, Jesús Zacarías Villarreal-Pérez, Ángel N Del Cueto-Aguilera, José A González-González & Giuseppe Pugliese. (2022) Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives. World Journal of Gastroenterology 28:8, pages 775-793.
Crossref
Crossref
Lung-Wen Tsai, Yi-Hsiang Lu, Rajni Dubey & Jeng-Fong Chiou. (2021) Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus. Journal of Diabetes Research 2021, pages 1-14.
Crossref
Crossref
Rui-Min Lai, Tian-Bin Chen, Yu-Hai Hu, Gui Wu & Qi Zheng. (2021) Effect of type 2 diabetic mellitus in the prognosis of acute-on-chronic liver failure patients in China. World Journal of Gastroenterology 27:23, pages 3372-3385.
Crossref
Crossref
Russell Rosenblatt, Preston Atteberry, Zaid Tafesh, Aarti Ravikumar, Carl V. Crawford, Catherine Lucero, Arun B. Jesudian, Robert S. BrownJrJr, Sonal Kumar & Brett E. Fortune. (2021) Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. Digestive and Liver Disease 53:4, pages 445-451.
Crossref
Crossref
Waihong Chung, Kittichai Promrat & Jack Wands. (2020) Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World Journal of Hepatology 12:9, pages 533-557.
Crossref
Crossref
Dalila Costa, Joana Lourenço, Ana Margarida Monteiro, Beatriz Castro, Patricia Oliveira, Maria Carmo Tinoco, Vera Fernandes, Olinda Marques, Raquel Gonçalves & Carla Rolanda. (2020) Clinical Performance of Flash Glucose Monitoring System in Patients with Liver Cirrhosis and Diabetes Mellitus. Scientific Reports 10:1.
Crossref
Crossref
Z A Kalmykova, I V Kononenko & A Yu Mayorov. (2019) Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features. Terapevticheskii arkhiv 91:12, pages 115-121.
Crossref
Crossref
Jisu Kim, Susin Park, Hyunsoo Kim & Nam Kyung Je. (2019) National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus. European Journal of Clinical Pharmacology 75:12, pages 1723-1730.
Crossref
Crossref
Z A Kalmykova, I V Kononenko & A Yu Mayorov. (2019) Diabetes mellitus and chronic liver diseases. Part 1: general mechanisms of etiology and pathogenesis. Terapevticheskii arkhiv 91:10, pages 106-111.
Crossref
Crossref
Athanasia Papazafiropoulou & Andreas Melidonis. (2019) Antidiabetic agents in patients with hepatic impairment. World Journal of Meta-Analysis 7:8, pages 380-388.
Crossref
Crossref
Valeria Grancini, Veronica Resi, Eva Palmieri, Giuseppe Pugliese & Emanuela Orsi. (2019) Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacological Research 141, pages 556-573.
Crossref
Crossref
Nobuya Inagaki, Wayne H.-H. Sheu, David R. Owens, Susanne Crowe, Amit Bhandari, Yan Gong & Sanjay Patel. (2016) Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. Journal of Diabetes and its Complications 30:8, pages 1622-1630.
Crossref
Crossref
Naoki Matsumoto, Masahiro Ogawa, Shunichi Matsuoka & Mitsuhiko Moriyama. (2016) Prevalence and Risk Factors of Diabetes Mellitus in Patients with Autoimmune Hepatitis. Internal Medicine 55:8, pages 879-885.
Crossref
Crossref
Diego García-Compeán, José A. González-González, Fernando J. Lavalle-González, Emmanuel I. González-Moreno, Héctor J. Maldonado-Garza & Jesús Z. Villarreal-Pérez. (2015) The treatment of diabetes mellitus of patients with chronic liver disease. Annals of Hepatology 14:6, pages 780-788.
Crossref
Crossref
Renee Y. Meadows. (2015) Optimal Glycemic Control in Hospitalized Patients. Hospital Medicine Clinics 4:4, pages 471-488.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 53:9, pages 773-785.
Crossref
Crossref
Ayami Kajiwara, Junji Saruwatari, Misaki Sakata, Kazunori Morita, Ayana Kita, Kentaro Oniki, Masato Yamamura, Motoji Murase, Haruo Koda, Seisuke Hirota, Tadao Ishizuka & Kazuko Nakagawa. (2013) Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture. Drug Safety 36:10, pages 981-987.
Crossref
Crossref
Diethelm Tschöpe, Markolf Hanefeld, Juris J Meier, Anselm K Gitt, Martin Halle, Peter Bramlage & Petra-Maria Schumm-Draeger. (2013) The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovascular Diabetology 12:1, pages 62.
Crossref
Crossref